Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Fortis, RHT Health...

    Fortis, RHT Health extend discussion time by 30 days

    Written by Ruby Khatun Khatun Published On 2018-01-15T10:00:56+05:30  |  Updated On 15 Jan 2018 10:00 AM IST
    Fortis, RHT Health extend discussion time by 30 days

    New Delhi: Fortis Health Management and Singapore-listed RHT Health Trust have extended exclusivity period to finalize the proposed acquisition by 30 more days from January 12.


    Fortis' board had approved the proposed acquisition of the entire portfolio of RHT Health Trust (RHT) for an enterprise value of around Rs 4,650 crore.


    Both the parties as per the agreed term sheet between them had entered into an exclusivity period for 60 days which expired on January 12, 2018.


    "It is hereby further informed that the parties to the Term Sheet have on January 12, 2018, mutually agreed to extend the Exclusivity Period by an additional period of 30 days from January 12, 2018.


    This is in order to facilitate the continued negotiations and finalisation of the definitive agreements in relation to the proposed transaction," Fortis said in a regulatory filing.


    The step is part of a restructuring initiative aimed at consolidating the entire Indian asset portfolio comprising various clinical establishments and two operating hospitals of RHT Health Trust into Fortis.


    Fortis has an indirect stake of 29.76 percent in RHT.


    For 2017-18, the net cumulative service fees to be paid by Fortis to RHT is estimated to be around Rs 270 crore.


    Upon completion of the securities acquisition, the service fees that Fortis was paying will be completely eliminated, as per details shared by the firm earlier.

    Acquisitionclinical establishmentsdefinitive agreementsdiscussion timeextendFortisFortis Health ManagementRHT Health TrustRHT portfoliotransaction
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok